Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 29Semaglutide literaturePubMed · Observational2025

GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.

This study found no acute intraoperative pulmonary aspiration among patients using GLP-1 receptor agonists before total joint arthroplasty, suggesting a low risk of anesthesia-related complications in this group.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
7
Preclinical
16
Observational · this one
0
Open-label
2
Randomised
4
Reviews

Summary and findings

This study assessed the incidence of intraoperative and early postoperative complications in patients using GLP-1 receptor agonists prior to total joint arthroplasty. A total of 83 patients were included, with 63 (75.9%) receiving semaglutide. No cases of acute intraoperative pulmonary aspiration were identified, and 4 patients (4.8%) experienced medical complications within 90 days.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
No cases of acute intraoperative pulmonary aspiration identified, n=83.2025

Abstract

The authors’ words, as PubMed supplied them

<h4>Introduction</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have recently garnered increased attention due to their effectiveness in inducing marked weight loss among overweight and obese adults. Recent evidence, however, has raised concerns about a potential link between GLP-1 receptor agonist therapy and perioperative pulmonary aspiration. In this single-institution retrospective series, we aimed to quantify the incidence of intraoperative and early postoperative complications among patients taking GLP-1 RA before elective total joint arthroplasty (TJA).<h4>Methods</h4>All patients who underwent primary TJA at our institution between April 2014 and October 2023 were initially screened. Patients were considered eligible for inclusion if they demonstrated consistent preoperative GLP-1 RA utilization. GLP-1 RA medication type, dosage, administration method, and treatment duration were tabulated for each patient. The primary outcomes of interest wereintraoperative anesthesia-related complications, particularly pulmonary aspiration, postoperative medical and surgical complications, and 90-day reoperation.<h4>Results</h4>In total, 83 patients demonstrated consistent GLP-1 RA usage before primary TJA. Of these patients, 63 (75.9%) received semaglutide, 19 (22.9%) liraglutide, and 1 (1.2%) tirzepatide. No cases of acute intraoperative pulmonary aspiration were identified. Intraoperative assessment of gastric contents was not routinely performed; however, one patient was noted to have a full stomach requiring nasogastric decompression. This individual was in the dose-escalation phase of treatment, having self-administered 1 mg of semaglutide five days before surgery. Four patients (4.8%) experienced 90-day medical complications, none of which were attributed to GLP-1 RA use, and one patient (1.2%) required reoperation.<h4>Conclusion</h4>Despite recent studies suggesting an elevated risk of acute intraoperative pulmonary aspiration, our findings underscore the rare nature of intraoperative anesthesia-related adverse events in TJA patients taking GLP-1 RA.

Background

The paper addresses the potential impact of GLP-1 receptor agonists on anesthesia-related complications during total joint arthroplasty. Prior research has suggested that certain medications may influence perioperative outcomes, but the specific role of GLP-1 receptor agonists in this context is not well established. This study aims to fill that gap by examining the relationship between these medications and anesthesia-related risks.

Methods

The study design is not specified in the abstract. The population includes patients undergoing total joint arthroplasty, but the exact sample size (n) is not reported. The dose and duration of GLP-1 receptor agonist administration are also not detailed. Primary and secondary outcome measures related to anesthesia complications are not specified.

Results

Not reported in abstract.

Interpretation

Without specific results, it is difficult to compare this study's findings to existing literature. The absence of reported effect sizes limits the ability to assess clinical significance. Potential confounds include the lack of detail on study design and population characteristics, which may affect the reliability of the conclusions drawn.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Semaglutide corpus

DCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026DEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026D1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.The lancet. Diabetes & endocrinology · 2026BComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.05HumanBGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubesbiorxiv-preprint · 2026 · Semaglutide reduced glycolytic and total ATP production rates, exact values not reported.HumanBReal-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiographybiorxiv-preprint · 2026 · LV mass decreased from 198.4 ± 69.6 g to 176.6 ± 66.0 g in super-responders, p < 0.001.Human